Martin Sorina, Mustata Theodor, Enache Oana, Ion Oana, Chifulescu Andreea, Sirbu Anca, Barbu Carmen, Miron Adrian, Giulea Cosmin, Andrei Florin, Fica Simona
Endocrinology Department, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Endocrinology Department, Elias Hospital, 011461 Bucharest, Romania.
Diagnostics (Basel). 2021 Oct 22;11(11):1959. doi: 10.3390/diagnostics11111959.
The primary endpoint was to analyze the preoperatory inflammatory markers and platelet indices in papillary thyroid cancer (PTC) patients compared with patients with benign thyroid pathology. The secondary endpoints were to analyze the relationship between these markers and the pathological features of PTC and to compare their pre- and postoperative levels in PTC patients.
In this retrospective case-control study, we analyzed the files of 1183 patients submitted to thyroidectomy between January 2012 and December 2018. A total of 234 patients with PTC (mean age 51.54 ± 13.10 years, 84.6% females) were compared with an age-, gender- and BMI-matched control group of 108 patients with histologic benign thyroid disorders.
PTC patients had higher platelet count (PLT) ( = 0.011), plateletcrit (PCT) ( = 0.006), neutrophil ( = 0.022) and fibrinogen ( = 0.005) levels. Subgroup analysis showed that PTC females had higher PLT ( = 0.006), PCT ( < 0.001) and erythrocyte sedimentation rate (ESR) ( = 0.005), while males had higher neutrophil ( = 0.040) levels. Papillary thyroid cancer patients under 55 years had higher PLT ( < 0.001) and PCT ( = 0.010), while patients over 55 years had higher mean platelet volume ( = 0.032), neutrophil-to-lymphocyte ratio ( = 0.013), ESR ( = 0.005) and fibrinogen ( = 0.019) levels. Preoperative values for platelet indices and inflammatory markers were similar to the postoperative determinations in PTC patients. Fibrinogen (AUROC = 0.602, = 0.02; cut-off = 327.5 mg/dL, Se = 53.8%, Sp = 62.9%) and PLT (AUROC = 0.584, = 0.012; cut-off = 223.5 × 10/mm, Se = 73.1%, Sp = 42.6%) were independent predictors of the presence of PTC.
Our data show that fibrinogen and platelet count could be promising, inexpensive, independent predictors for the presence of PTC when compared with benign thyroid disorders.
主要终点是分析甲状腺乳头状癌(PTC)患者与甲状腺良性病变患者术前的炎症标志物和血小板指标。次要终点是分析这些标志物与PTC病理特征之间的关系,并比较PTC患者术前和术后的水平。
在这项回顾性病例对照研究中,我们分析了2012年1月至2018年12月期间接受甲状腺切除术的1183例患者的病历。将234例PTC患者(平均年龄51.54±13.10岁,84.6%为女性)与108例组织学诊断为甲状腺良性疾病且年龄、性别和BMI匹配的对照组进行比较。
PTC患者的血小板计数(PLT)(P = 0.011)、血小板压积(PCT)(P = 0.006)、中性粒细胞(P = 0.022)和纤维蛋白原(P = 0.005)水平较高。亚组分析显示,PTC女性患者的PLT(P = 0.006)、PCT(P < 0.001)和红细胞沉降率(ESR)(P = 0.005)较高,而男性患者的中性粒细胞(P = 0.040)水平较高。55岁以下的甲状腺乳头状癌患者的PLT(P < 0.001)和PCT(P = 0.010)较高,而55岁以上的患者的平均血小板体积(P = 0.032)、中性粒细胞与淋巴细胞比值(P = 0.013)、ESR(P = 0.005)和纤维蛋白原(P = 0.019)水平较高。PTC患者血小板指标和炎症标志物的术前值与术后测定值相似。纤维蛋白原(曲线下面积 = 0.602,P = 0.02;临界值 = 327.5 mg/dL,灵敏度 = 53.8%,特异度 = 62.9%)和PLT(曲线下面积 = 0.584,P = 0.012;临界值 = 223.5×10⁹/mm³,灵敏度 = 73.1%,特异度 = 42.6%)是PTC存在的独立预测指标。
我们的数据表明,与甲状腺良性疾病相比,纤维蛋白原和血小板计数可能是有前景、廉价的PTC存在的独立预测指标。